SkinCure Oncology: Comprehensive Company Profile

Background

Overview

SkinCure Oncology, established in 2016, is a leading provider of non-surgical treatments for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma. The company specializes in Image-Guided Superficial Radiation Therapy (IG-SRT), offering a minimally invasive alternative to traditional surgical methods. Headquartered in Burr Ridge, Illinois, SkinCure Oncology partners with dermatology practices across the United States to deliver advanced skin cancer treatments.

Mission and Vision

SkinCure Oncology's mission is to empower patients and dermatology practices by providing the highest level of education and expertise needed to deliver superior outcomes for non-melanoma skin cancer. Their vision is to be recognized as the preeminent patient-focused, industry thought, and market leader in the diagnosis and treatment of non-melanoma skin cancer and other skin conditions.

Industry Significance

SkinCure Oncology plays a pivotal role in the dermatology and oncology sectors by offering a non-invasive treatment option that preserves healthy tissue and minimizes recovery time. Their approach addresses the growing demand for effective, patient-friendly alternatives to traditional skin cancer treatments.

Key Strategic Focus

Core Objectives

• Expansion of Treatment Accessibility: Increase the availability of IG-SRT by partnering with more dermatology practices nationwide.

• Technological Advancement: Continuously enhance treatment precision and outcomes through the integration of advanced technologies.

• Patient Education and Empowerment: Provide comprehensive information to patients and clinicians to facilitate informed treatment decisions.

Areas of Specialization

• Non-Melanoma Skin Cancer Treatment: Focus on basal cell carcinoma and squamous cell carcinoma.

• Image-Guided Superficial Radiation Therapy (IG-SRT): Utilize advanced radiation therapy techniques for non-invasive treatment.

Key Technologies Utilized

• Sensus SRT-100 Vision™: A state-of-the-art platform for delivering IG-SRT with high-frequency ultrasound imaging.

• GentleBeam™: An FDA-cleared imaging tool that enhances treatment planning and precision.

Primary Markets Targeted

• Dermatology Practices: Collaborate with dermatologists and Mohs surgeons to integrate IG-SRT into their treatment offerings.

• Patients Seeking Non-Surgical Options: Provide an alternative to traditional surgical treatments for skin cancer patients.

Financials and Funding

Funding History

SkinCure Oncology has successfully raised a total of $33.47 million across seven funding rounds. The most recent funding activity was a Series C round of $30 million completed in August 2019.

Notable Investors

• Seacoast Capital Partners: Provided non-control growth capital to support the company's expansion.

• Capx Partners: Invested in the company's growth-stage initiatives.

Utilization of Capital

The raised capital has been allocated towards:

• Technological Development: Enhancing treatment platforms like GentleBeam™.

• Operational Expansion: Increasing the number of practice partnerships and geographic reach.

• Clinical Research: Conducting studies to validate treatment efficacy and patient outcomes.

Pipeline Development

Key Pipeline Candidates

• GentleBeam™: An advanced imaging tool designed to improve treatment precision and patient outcomes.

Stages of Development

• FDA Clearance: GentleBeam™ received FDA clearance in March 2026, marking a significant milestone in the company's technological advancement.

Target Conditions

• Non-Melanoma Skin Cancer: Specifically targeting basal cell carcinoma and squamous cell carcinoma.

Anticipated Milestones

• Implementation: Integrate GentleBeam™ into existing dermatology practice partnerships.

• Clinical Validation: Monitor and report on treatment outcomes to validate the efficacy of the new technology.

Technological Platform and Innovation

Proprietary Technologies

• GentleBeam™: An FDA-cleared imaging tool that enhances treatment planning and precision.

Significant Scientific Methods

• Photosonic™ Technology: Utilized in GentleBeam™ to generate acoustic pressure waves for visualizing skin layers and blood vessels, improving treatment precision.

Leadership Team

Executive Profiles

• Kerwin J. Brandt: Chief Executive Officer

• Professional Background: Over 25 years in healthcare financing and transactions, with more than 20 years of leadership experience in healthcare start-ups and business ventures.

• Key Contributions: Served as CEO of Accelitech for 11 years and raised over $150 million in project capital in the healthcare space.

• Steven L. Scott: Executive Vice President, Chief Strategy & Innovation Officer

• Professional Background: Thirty years of healthcare experience, including regional oncology direction for HCA and sales/strategic account management for Varian Medical Systems.

• Key Contributions: Served as COO and radiation safety officer for a large dermatology practice, more than doubling its footprint and EBITDA margin.

• Dr. Daniel J. Ladd Jr.: Chief Medical Officer

• Professional Background: Board-certified dermatologist and Mohs surgeon with ownership of seven comprehensive dermatology offices.

• Key Contributions: Former president of the American Osteopathic College of Dermatology and pioneer in dermatology-driven IG-SRT.

• Joshua Swindle: Chief Operating Officer

• Professional Background: 15 years of healthcare experience, including roles as Chief Radiation Therapist and Director of Business Development.

• Key Contributions: Served as Chief Radiation Therapist for Centers for Cancer Care and Phoenix Oncology.

• Cathryn Klimek: Chief Financial Officer

• Professional Background: 15 years of finance and accounting experience.

• Key Contributions: Oversees financial operations and strategic financial planning for the company.

Competitor Profile

Market Insights and Dynamics

The non-melanoma skin cancer treatment market is experiencing growth due to increasing skin cancer incidences and a shift towards non-invasive treatment options. Technological advancements and patient preference for minimally invasive procedures are driving market dynamics.

Competitor Analysis

• US Oncology Network: Provides comprehensive cancer care through a network of specialized hospitals.

• OneOncology: Partners with independent community oncology practices to enhance care delivery.

• The Oncology Institute of Hope and Innovation: Delivers cancer care services via a hospital chain.

• 21st Century Oncology: Operates a network of specialized hospitals focused on cancer care.

• Memorial Sloan Kettering Cancer Center: Renowned for oncology hospitals focused on cancer care and research.

Strategic Collaborations and Partnerships

SkinCure Oncology collaborates with dermatology practices nationwide, providing them with the necessary equipment, training, and operational support to offer IG-SRT. This partnership model enhances the availability and accessibility of non-surgical skin cancer treatments.

Operational Insights

SkinCure Oncology differentiates itself by offering a comprehensive support system to dermatology practices, including clinical, administrative, and operational backing. This approach enables practices to integrate advanced non-surgical treatments seamlessly, enhancing patient care and expanding service offerings.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Expansion of Practice Partnerships: Increase the number of dermatology practices offering IG-SRT to broaden patient access.

• Technological Innovation: Continue developing and integrating advanced technologies like GentleBeam™ to improve treatment precision and outcomes.

• Patient Education Initiatives: Enhance educational efforts to inform patients and clinicians about the benefits and availability of non-surgical skin cancer treatments.